Saturday, 14 November 2015

More on the 4th case of PML in a pwMS on Tecfidera

Rumours about a 4th case of PML in a 61 year old MSer have been confirmed. What is not mentioned in the report is whether Tysabri played a role, but I suspect it didn't given the potential benefit for Biogen's share price of blaming natalizumab instead of Tecfidera.

4 comments:

  1. Study reporting a variant of JCV that causes PML severe http://www.ncbi.nlm.nih.gov/pubmed/26498276

    ReplyDelete
  2. The Medscape summary states that the patient "had previously taken natalizumab (Tysabri) for 6 years and 4 months, but the company said that prior exposure wasn't considered a confounder in this case".

    http://www.medpagetoday.com/Neurology/MultipleSclerosis/54704

    Any comments?

    ReplyDelete
    Replies
    1. The webpage link that Anon at 7:43:00pm put states

      "The patient had previously taken natalizumab (Tysabri) for 6 years and 4 months, but the company said that prior exposure wasn't considered a confounder in this case. She'd also taken interferon beta-1a (Avonex) and intravenous immunoglobulin.

      Few other details about the case were made available. Neither Biogen nor the FDA or the European Medicines Agency (EMA) would comment on the case. "

      Delete
  3. hi when I took the tysabri I swear it made worse in 4 months ,.I wasn't worried on the pml but calling company on the sever disability they couldn't answer. any thoughts

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.